December 12, 2018

Deal Snapshot: Eli Lilly & AC Immune in Alzheimer’s

Eli Lilly’s relevant synergies with the licensed asset (ACI-3024)

  • Deal Headline: Lilly and AC Immune to Collaborate on Tau Aggregation Inhibitors (12th Dec 2018)
  • Licensee: Eli Lilly and Company
  • Licensor: AC Immune
  • Therapeutic Area: CNS
  • Asset: ACI-3024
  • Technology: Small molecule inhibitors
  • Target: Tau
  • Phase: Pre-Clinical
  • Deal Type: License and collaboration
  • Other “Under the terms of the agreement, AC Immune will receive an upfront payment of CHF80 million as well as $50 million in exchange for a note, convertible to equity at a premium.”

  • Upfront: CHF 80M
  • Equity: USD 50M
  • Milestones: CHF 1760M
  • Total Deal Value: CHF 1889.7M
  • Royalties: Tiered sales royalties in the low double digits
  • Territory: Worldwide

Eli Lilly Key BD Contacts

Eli Lilly Deal Activity by Therapeutic Area (Last 3 Years)

33% Oncology, 19% CNS, 20% Diabetes, 14% Immunology, 14% Other

Recent deals:

Eli Lilly Pipeline Composition

33% Oncology, 29% Immunology, 25% Diabetes, 13% CNS

Lead CNS Assets:

Asset Indication Stage
Flortaucipir F 18 Imaging agent for Tau pathology Phase III
Solanezumab Alzheimer’s disease Phase III
LY3002813 Alzheimer's disease Phase II

Business profiles tailored to your asset.